Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc.AUPH · Entity 4463 | Chief Legal Officer | September 10, 2026 | September 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aurinia Pharmaceuticals Inc.
Report date September 10, 2026 · Filed September 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 588,848 |
Reported balance
After 2026-09-10 transaction · row 1
1 source rowRow 1 · 2026-09-10 · Sale · Disposed 11,939 · Balance 588,848 F1: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Performance Stock Units (PSUs) related to the February 28, 2025 performance award. F2: The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.95 to $15.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Performance Stock Units (PSUs) related to the February 28, 2025 performance award.
F2: The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.95 to $15.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 10, 2026 Filed Sep 11, 2026 20:26 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 11,939 | $15.95 | $190,427.05 |
DisclosureSEC source: 0001600620-26-000068 · wk-form4_1789158362.xml · nonDerivative · entry 1 Robertson Stephen P. · CIK 0001837798 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 588,848 F1 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Performance Stock Units (PSUs) related to the February 28, 2025 performance award. F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.95 to $15.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 21, 2026 Filed Aug 26, 2026 01:29 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 20,975 | $16.97 | $355,945.75 |
DisclosureSEC source: 0001837798-26-000013 · wk-form4_1787707766.xml · nonDerivative · entry 1 Robertson Stephen P. · CIK 0001837798 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,787 F1 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Performance Stock Units (PSUs) related to the February 28, 2025 performance award. F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.96 to $17.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 360 common shares that were acquired on May 29, 2026 by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan. Read SEC document |
| May 18, 2026 Filed May 20, 2026 21:05 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantCommon Stock | 115,541 | $0.00 | $0.00 |
DisclosureSEC source: 0001837798-26-000005 · wk-form4_1779311116.xml · nonDerivative · entry 1 Robertson Stephen P. · CIK 0001837798 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 621,402 F1 · shares: Each performance stock unit ("PSU") represents a contingent right to receive one common share of the Issuer. 115,541 PSUs vest in two tranches at the three and five year anniversary date of grant if the Issuer's common shares achieve target prices that represent significant increases from the share price on date of grant before the respective vesting date. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:12 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Tax withholdingCommon Stock | 36,525 | $14.21 | $519,020.25 |
DisclosureSEC source: 0001600620-26-000019 · wk-form4_1772572374.xml · nonDerivative · entry 2 Robertson Stephen P. · CIK 0001837798 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 505,861 F2 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:12 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantEmployee Stock Option (right to buy) · Derivative | 98,813 | $0.00 Strike: $13.97 | $0.00 |
DisclosureSEC source: 0001600620-26-000019 · wk-form4_1772572374.xml · derivative · entry 3 Robertson Stephen P. · CIK 0001837798 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,813 Underlying: Common Stock · 98,813 shares Expires 2036-02-27 F3 · derivative.exercise_date: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:12 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantCommon Stock | 59,090 | $0.00 | $0.00 |
DisclosureSEC source: 0001600620-26-000019 · wk-form4_1772572374.xml · nonDerivative · entry 1 Robertson Stephen P. · CIK 0001837798 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 542,386 F1 · shares: Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 21:04 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Tax withholdingCommon Stock | 34,638 | $14.40 | $498,787.20 |
DisclosureSEC source: 0001837798-26-000002 · wk-form4_1771880670.xml · nonDerivative · entry 1 Robertson Stephen P. · CIK 0001837798 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 483,296 F1 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 21:13 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Tax withholdingCommon Stock | 40,385 | $15.95 | $644,140.75 |
DisclosureSEC source: 0001600620-26-000005 · wk-form4_1767647607.xml · nonDerivative · entry 2 Robertson Stephen P. · CIK 0001837798 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 517,934 F2 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of performance awards. F3 · balance_after: Includes common shares acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 531 common shares were acquired on May 30, 2025 and 354 common shares were acquired on November 28, 2025. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 21:13 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantCommon Stock | 48,558 | $0.00 | $0.00 |
DisclosureSEC source: 0001600620-26-000005 · wk-form4_1767647607.xml · nonDerivative · entry 1 Robertson Stephen P. · CIK 0001837798 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 557,434 F1 · shares: Represents the number of shares earned upon certification of performance for a performance award payable solely in common shares of the Issuer that vest in two (2) equal annual installments on December 31, 2025 and December 31, 2026. Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 01:57 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 57,607 | $7.92 | $456,247.44 |
DisclosureSEC source: 0001600620-25-000019 · wk-form4_1741139835.xml · nonDerivative · entry 4 Robertson Stephen P. · CIK 0001837798 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 509,276 F6 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of RSUs related to the March 2, 2022 and March 2, 2023 grants. F7 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.76 to $8.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 01:57 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 64,872 | $8.00 | $518,976.00 |
DisclosureSEC source: 0001600620-25-000019 · wk-form4_1741139835.xml · nonDerivative · entry 3 Robertson Stephen P. · CIK 0001837798 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 566,883 F4 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) related to the February 20, 2024 grant and March 2, 2023 performance award. F5 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.79 to $8.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 01:57 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantCommon Stock | 102,406 | $0.00 | $0.00 |
DisclosureSEC source: 0001600620-25-000019 · wk-form4_1741139835.xml · nonDerivative · entry 2 Robertson Stephen P. · CIK 0001837798 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 631,755 F3 · shares: Represents grant of performance award payable solely in common shares of the Issuer that vest in two (2) equal annual installments on December 31, 2024 and December 31, 2025. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 01:57 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantEmployee Stock Option (right to buy) · Derivative | 128,438 | $0.00 Strike: $7.55 | $0.00 |
DisclosureSEC source: 0001600620-25-000019 · wk-form4_1741139835.xml · derivative · entry 5 Robertson Stephen P. · CIK 0001837798 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,438 Underlying: Common Stock · 128,438 shares Expires 2035-02-28 F8 · derivative.exercise_date: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 01:57 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantCommon Stock | 84,106 | $0.00 | $0.00 |
DisclosureSEC source: 0001600620-25-000019 · wk-form4_1741139835.xml · nonDerivative · entry 1 Robertson Stephen P. · CIK 0001837798 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 529,349 F1 · shares: Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement. F2 · balance_after: Includes common shares acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 513 common shares were acquired on May 31, 2024 and 506 common shares were acquired on November 29, 2024. Read SEC document |
| March 06, 2024 Filed Mar 7, 2024 21:41 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 57,745 | $5.60 | $323,372.00 |
DisclosureSEC source: 0001600620-24-000034 · wk-form4_1709847708.xml · nonDerivative · entry 1 Robertson Stephen P. · CIK 0001837798 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 443,824 F1 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Restricted Stock Units related to the March 2, 2022 and March 2, 2023 grants. F2 · price: The price in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.475 to $5.755, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 21:29 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantCommon Stock | 194,230 | $0.00 | $0.00 |
DisclosureSEC source: 0001600620-24-000019 · wk-form4_1708637344.xml · nonDerivative · entry 1 Robertson Stephen P. · CIK 0001837798 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 501,569 F1 · shares: Represents grant of Restricted Stock Units (RSUs) payable solely in common stock of the Issuer that vest in three (3) equal annual installments on the first, second and third anniversary of the grant date. F2 · balance_after: Includes shares of common stock acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 2,500 shares of common stock were acquired on May 31, 2023 and 1,717 shares of common stock were acquired on November 30, 2023. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 21:29 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 19,402 | $8.94 | $173,453.88 |
DisclosureSEC source: 0001628280-23-006530 · wf-form4_167813813532555.xml · nonDerivative · entry 2 Robertson Stephen P. · CIK 0001837798 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,364 F5 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 21:29 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantCommon Stock | 204,810 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-006530 · wf-form4_167813813532555.xml · nonDerivative · entry 1 Robertson Stephen P. · CIK 0001837798 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,766 F1 · shares: Represents grant of Restricted Stock Units (RSUs) payable solely in common stock of the Issuer that vest in three (3) equal annual installments on the first, second and third anniversary of the grant date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F3 · balance_after: Includes shares of common stock acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 2,016 shares of common stock were acquired on May 31, 2022 and 178 shares of common stock were acquired on November 30, 2022. F4 · balance_after: The reporting person has reported prior awards of restricted stock units in Table II of Form 4. The total reported in Column 5 includes the 204,810 newly awarded RSUs, 104,080 RSUs previously reported in Table II, which vests in three (3) equal annual installments beginning March 2, 2022 (Prior RSUs), and 11,682 shares of common stock. On March 2, 2023, 34,693 of Prior RSUs vested and 69,387 of Prior RSUs remained unvested. Read SEC document |
| March 02, 2023 Filed Feb 22, 2024 21:19 UTC Amendment | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 19,644 | $8.78 | $172,474.32 |
DisclosureSEC source: 0001600620-24-000015 · wk-form4a_1708636769.xml · nonDerivative · entry 1 Robertson Stephen P. · CIK 0001837798 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 303,122 F1 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:11 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantStock Option (right to buy) · Derivative | 178,063 | $0.00 Strike: $12.01 | $0.00 |
DisclosureSEC source: 0001628280-22-005121 · wf-form4_164642825231972.xml · derivative · entry 3 Robertson Stephen P. · CIK 0001837798 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,063 Underlying: Common Stock · 178,063 shares Expires 2032-03-02 F4 · derivative.exercise_date: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:11 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantRestricted Stock Unit · Derivative | 104,080 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-005121 · wf-form4_164642825231972.xml · derivative · entry 2 Robertson Stephen P. · CIK 0001837798 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,080 Underlying: Common Shares · 104,080 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. F3 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. F3 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:11 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantCommon Stock | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-005121 · wf-form4_164642825231972.xml · nonDerivative · entry 1 Robertson Stephen P. · CIK 0001837798 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,682 F1 · shares: On March 18, 2021, the Reporting Person was granted stock based performance awards ("Performance Awards") which vests when specific performance metrics are met based on the results for the year ended December 31, 2021. It was determined that as of March 2, 2022, the Reporting Person partially met the performance criteria and received shares of common stock for no consideration. F2 · balance_after: Includes 462 shares acquired by the Reporting Person under the Issuer's 2021 Employee Share Purchase Plan on December 1, 2021. Read SEC document |
| January 28, 2021 Filed Jan 29, 2021 17:24 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | PurchaseCommon Stock | 900 | $16.14 | $14,526.00 |
DisclosureSEC source: 0001628280-21-001096 · wf-form4_161194104312841.xml · nonDerivative · entry 1 Robertson Stephen P. · CIK 0001837798 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,720 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.